Recently we hypothesized that, in the PNS, the Schwann cells are the primary target for GABA’s action, as shown by the presence of mRNAs coding for a variety of GABA-A and GABA-B receptor subunits (Magnaghi, Curr. Neuropharmacol. 2007). Allopregnanolone (ALLO), a reduced metabolite of progesterone, modulates GABA-A receptor in Schwann cells and increases mRNA and protein levels of PMP22 (Magnaghi, Brain Res Rev. 2001). This observation is supported by the evidence that muscimol (a selective GABA-A agonist) similarly enhances PMP22 mRNA levels, whereas bicuculline (a specific GABA-A antagonist) counteracts such increase (Magnaghi, Brain Res Rev. 2001). Therefore, the expression of PMP22 in Schwann cells seems to be under control of GABA-A receptor. In addition, ALLO induces a robust stimulation of the mRNAs coding for some GABA-B receptor subunits. These effects are partially mimicked by muscimol, suggesting that ALLO controls GABA-B receptor expression through GABA-A mediated mechanism (Magnaghi, J Mol. Neurosci 2006). However, the general mechanism downstream ALLO activation of GABA-A is still elusive. Consequently, we aimed at elucidating ALLO’s-mediated mechanism(s) in Schwann cells, and its putative effects on GABA synthesis. By means of different approaches we demonstrated the presence of glutamic acid decarboxylase of 67 kDa (GAD67) in Schwann cells; additionally we demonstrated that GABA is synthesized and localized in Schwann cells. Finally, we suggested that PKA pathway, through enhanced cAMP levels and CREB phosphorylation is the intracellular signalling pathway responsible for such an allosteric action of ALLO at GABA-A receptor in Schwann cells. The knowledge of these mechanisms, therefore, might be important to establish new putative strategies to treat peripheral neuropathies.

Synthesis of Gaba in Schwann cells is induced by the neuroactive steroid allopregnanolone / V. Magnaghi, G. Bonanno, A. Faroni, A. Parducz, F. Fumagalli. - In: JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. - ISSN 1085-9489. - 14:suppl. 2(2009 Jul), pp. 93-94. ((Intervento presentato al convegno Meeting of the Peripheral nerve society tenutosi a Würzburg nel 2009.

Synthesis of Gaba in Schwann cells is induced by the neuroactive steroid allopregnanolone

V. Magnaghi
Primo
;
F. Fumagalli
Ultimo
2009-07

Abstract

Recently we hypothesized that, in the PNS, the Schwann cells are the primary target for GABA’s action, as shown by the presence of mRNAs coding for a variety of GABA-A and GABA-B receptor subunits (Magnaghi, Curr. Neuropharmacol. 2007). Allopregnanolone (ALLO), a reduced metabolite of progesterone, modulates GABA-A receptor in Schwann cells and increases mRNA and protein levels of PMP22 (Magnaghi, Brain Res Rev. 2001). This observation is supported by the evidence that muscimol (a selective GABA-A agonist) similarly enhances PMP22 mRNA levels, whereas bicuculline (a specific GABA-A antagonist) counteracts such increase (Magnaghi, Brain Res Rev. 2001). Therefore, the expression of PMP22 in Schwann cells seems to be under control of GABA-A receptor. In addition, ALLO induces a robust stimulation of the mRNAs coding for some GABA-B receptor subunits. These effects are partially mimicked by muscimol, suggesting that ALLO controls GABA-B receptor expression through GABA-A mediated mechanism (Magnaghi, J Mol. Neurosci 2006). However, the general mechanism downstream ALLO activation of GABA-A is still elusive. Consequently, we aimed at elucidating ALLO’s-mediated mechanism(s) in Schwann cells, and its putative effects on GABA synthesis. By means of different approaches we demonstrated the presence of glutamic acid decarboxylase of 67 kDa (GAD67) in Schwann cells; additionally we demonstrated that GABA is synthesized and localized in Schwann cells. Finally, we suggested that PKA pathway, through enhanced cAMP levels and CREB phosphorylation is the intracellular signalling pathway responsible for such an allosteric action of ALLO at GABA-A receptor in Schwann cells. The knowledge of these mechanisms, therefore, might be important to establish new putative strategies to treat peripheral neuropathies.
Feasibility; Intravenous immunoglobulin; Multifocal motor neuropathy; Subcutaneous immunoglobulin; Therapy
Settore MED/13 - Endocrinologia
Settore BIO/14 - Farmacologia
Article (author)
File in questo prodotto:
File Dimensione Formato  
c50e77405efb1f54c34ff9016ea1eec4042ee06641e0125523bbaf2d417ff11a.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 1.44 MB
Formato Adobe PDF
1.44 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/70212
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact